Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Unlabelled: The SARS-CoV-2 pandemic significantly affected clinical practice worldwide. In Italy, hospital access was limited to urgent cases in 2020. The primary aim was to assess the impact of SARS-CoV-2 on pIBD in Italy during 2020 compared to 2019 and to 2021. The secondary aim was to compare characteristics of pIBD during 2019-2021 with data from previous reports. All new pIBD diagnoses from January 1st, 2019, to December 31st, 2021, were collected through the IBD registry of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP) and compared with data from previous studies. A total of nine-hundred-seventy-six new pIBD diagnoses were registered over a three-year period. The lowest number was recorded in 2020 (n = 267), significantly fewer than in 2019 and 2021 (p = 0.003). The mean incidence was 3.43/100000/year compared to 1.98 in 2009-2018 (p < 0.0001). The median diagnostic delay further decreased compared to previous years despite the COVID-19 outbreak, setting at 3.6 months. The overall median age at diagnosis was significantly higher than in 2009-2018 (12.8 vs 11.7 years, p < 0.001). The use of anti-TNF-alpha agents as induction therapy significantly increased during 2019-2021 (15.3%) compared to previous reports (6.6%).
Conclusions: In 2020 the lowest pIBD incidence was observed, likely due to impact of the COVID-19 outbreak. A subsequent rise in incidence in 2021 and a reduction in diagnostic delay were noted, possibly due to the easing of restrictions. Compared to previous Italian studies, the period 2019-2021 showed an overall increase in pIBD incidence and a decrease in diagnostic delay.
What Is Known: • Pediatric Inflammatory Bowel Diseases (pIBD) incidence is increasing worldwide, primarily in industrialized countries. • During SARS-CoV-2 pandemic, patients tended to postpone the use of medical cares and hospital accesses were limited to emergencies.
What Is New: • In Italy, during years 2019-2021, pIBD incidence increased and pIBD diagnostic delay shortened compared to the past, despite COVID-19 outbreak. • Prevalence of pIBD in adolescents during 2019-2021 turned out to be higher compared to previous reports. • Despite restrictions, the use of anti-TNF-alpha agents significantly increased compared to previous Italian reports.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00431-025-06422-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.
Lancet Rheumatol
September 2025
Academic Rheumatology, University of Nottingham, Nottingham, UK.
Background: Allopurinol, the most prescribed urate-lowering drug, is a known cause of severe cutaneous adverse reactions. We aimed to develop and validate a model to assess the risk of allopurinol-induced severe cutaneous adverse reactions in adults newly prescribed allopurinol.
Methods: In this retrospective new-user cohort study, we developed and validated a prognostic model using primary care, hospitalisation, and mortality data extracted from the UK Clinical Practice Research Datalink (CPRD) primary care database, for the period Jan 1, 2001, to March 29, 2021.
Safety of artificial intelligence-assisted optical diagnosis for leaving colorectal polyps in situ during colonoscopy (PRACTICE): a non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
October 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Endoscopy Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Background: Guidelines recommend leaving in situ rectosigmoid polyps diagnosed during colonoscopy that are 5 mm or smaller if the endoscopist optically predicts them to be non-neoplastic. However, no randomised controlled trial has been done to examine the efficacy and safety of this strategy.
Methods: This open-label, multicentre, non-inferiority, randomised controlled trial enrolled adults age 18 years or older undergoing colonoscopy for screening, surveillance, or clinical indications across four Italian centres.
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.
Nat Med
September 2025
Prilenia Therapeutics B.V., Naarden, the Netherlands.
Huntington's disease (HD) is a rare, neurodegenerative disorder for which only symptomatic treatments are available. The PROOF-HD study was a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of pridopidine, a selective Sigma-1 receptor agonist, in HD. The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.
View Article and Find Full Text PDF24-h urine test application in patients with kidney stone disease: a population-based study in a primary care setting.
J Nephrol
September 2025
Italian Society of General Medicine (SIMG), COMEGEN Primary Care Physicians Cooperative, Naples, Italy.
Background: Kidney stone formation is driven by an imbalance between lithogenic substances and crystallization inhibitors. Current guidelines recommend a 24-h urine collection in patients with kidney stone disease to assess the risk of stone formation and monitor therapy compliance. However, real-world data on adherence to these guidelines remain limited and outdated.
View Article and Find Full Text PDFGastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry.
Rheumatology (Oxford)
September 2025
Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy.
Objectives: To describe the prevalence of gastrointestinal (GI) symptoms in systemic sclerosis (SSc) and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement, and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry.
Methods: This cross-sectional analysis included patients fulfilling 2013 ACR/EULAR SSc or VEDOSS criteria. GI involvement was defined as symptoms in at least one GI tract segment and categorized as upper and lower.